Genentech Entered into an Exclusive WW License Agreement with Jemincare to Develop and Commercialize JMKX002992 for Prostate Cancer
- Jemincare to receive $60M up front & is also eligible to receive ~$590M in additional fees upon achievement of development, regulatory and sales-based milestones along with royalties on net sales. The collaboration focuses to develop new treatment options for patients with advanced prostate cancer
- Jemincare to get an exclusive license to develop and commercialize JMKX002992 globally Genentech will be fully responsible for the development and commercialization costs
- JMKX002992 is a novel oral degrader of the androgen receptor & is indicated to treat patients with prostate cancer who have developed resistance to current therapies
Ref: PRNewswire| Image: Genentech
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.